menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. , June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , today announced the closing of an underwritten public offering of
Read More

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , June 02, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today the pricing of an underwritten public offering of
Read More

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced today that it has commenced an underwritten public
Read More

Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments

Regeneron and Intellia to co-develop potential hemophilia A and B treatments using their jointly-owned targeted transgene insertion capabilities Regeneron gains rights to develop products for additional in vivo targets and new rights for ex vivo product development Intellia receives $100 million
Read More

Intellia Therapeutics Reports Progress on CRISPR/Cas9 AML Cancer Therapy Using Proprietary Cell Engineering Process at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

Intellia’s CRISPR/Cas9 proprietary process produces multiple, highly efficient sequential edits in T cells that have superior function and minimal translocations, compared to results from standard T cell engineering approaches Proprietary process supports NTLA-5001 and other potential therapies for
Read More

Intellia Therapeutics Announces First Quarter 2020 Financial Results

On track to submit an IND or IND-equivalent for NTLA-2001 for the treatment of transthyretin amyloidosis in mid-2020; plans to dose first patient in 2H 2020 On track to submit an IND or IND-equivalent for lead TCR-T cell therapy, NTLA-5001 for the treatment of acute myeloid leukemia, in 1H 2021
Read More

Intellia Therapeutics Names David Lebwohl, M.D., Chief Medical Officer

CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl , M.D., as its new executive vice president and chief medical officer. Dr. Lebwohl brings decades of biopharmaceutial leadership and drug development experience, and joins
Read More

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2020 Earnings and Company Updates

CAMBRIDGE, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its first quarter 2020 financial results and operational
Read More

Intellia Therapeutics to Present New Preclinical Data from Its CRISPR/Cas9 Programs at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

Company to Present Three Oral and Two Poster Presentations on In Vivo and Engineered Cell Therapy Pipeline Programs CAMBRIDGE, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using
Read More

FDA Accepts Investigational New Drug Application for CRISPR/Cas9-Based Sickle Cell Disease Therapeutic Candidate Developed Under Collaboration with Intellia Therapeutics

CAMBRIDGE, Mass. , March 31, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both  in vivo  and  ex vivo , announced that the U.S.
Read More
RSS FEEDS
PRINT PAGE